Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.

MLA

Belch, Andrew, et al. “Continuous Lenalidomide and Low-Dose Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed MM: FIRST Trial Subanalysis of Canadian/US Patients.” Cancer Medicine, vol. 9, no. 23, Dec. 2020, pp. 8923–30. EBSCOhost, https://doi.org/10.1002/cam4.3511.

APA

Belch, A., Bahlis, N., White, D., Cheung, M., Chen, C., Shustik, C., Song, K., Tosikyan, A., Dispenzieri, A., Anderson, K., Brown, D., Robinson, S., Srinivasan, S., & Facon, T. (2020). Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer Medicine, 9(23), 8923–8930. https://doi.org/10.1002/cam4.3511

Chicago

Belch, Andrew, Nizar Bahlis, Darrell White, Matthew Cheung, Christine Chen, Chaim Shustik, Kevin Song, et al. 2020. “Continuous Lenalidomide and Low-Dose Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed MM: FIRST Trial Subanalysis of Canadian/US Patients.” Cancer Medicine 9 (23): 8923–30. doi:10.1002/cam4.3511.